Clinical experience with daptomycin in Italy: Results from a registry study of the treatment of Gram-positive infections between 2006 and 2009

Riccardo Utili, Alberto Cogo, Francesco Cristini, Vincenzo Prisco, Evangelista Sagnelli, Carlo Tascini, Cinzia Iacoboni, Alessandro Capone, Gianni Gattuso, Gioacchino Angarano, Enzo Petrelli, Paolo Grossi, Marta Bartezaghi, Emanuela Zagni

Research output: Contribution to journalArticle

Abstract

The purpose of this study was to evaluate post-marketing efficacy and safety data for therapy with daptomycin (DAP) in Italy. Data from patients treated with DAP at 30 centres between January 2006 and July 2009 were analysed according to the protocol of the EU-CORESM. In 359 patients, DAP was most commonly prescribed for skin and skin-structure infections (55%), infective endocarditis (13%), and bacteraemia (12.5%). DAP was associated with rapid improvement, and clinical success rates ranging from 77 to 91%, despite almost half of the patient population being ≥65 years of age, 86% having significant underlying disease, and many being affected by drug-resistant pathogens. Staphylococcus aureus represented 35% of all pathogens isolated. Success rates for all staphylococcal and enterococcal infections were >80%, including methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA). Clinical outcomes were similar for DAP whether used as first- or second-line therapy. DAP was well tolerated even with prolonged treatment.

Original languageEnglish
Pages (from-to)113-121
Number of pages9
JournalJournal of Chemotherapy
Volume24
Issue number2
DOIs
Publication statusPublished - Apr 2012

Keywords

  • Bacteraemia
  • Daptomycin
  • Endocarditis
  • MRSA
  • MSSA
  • Skin and skin-structure infection

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology

Fingerprint Dive into the research topics of 'Clinical experience with daptomycin in Italy: Results from a registry study of the treatment of Gram-positive infections between 2006 and 2009'. Together they form a unique fingerprint.

  • Cite this

    Utili, R., Cogo, A., Cristini, F., Prisco, V., Sagnelli, E., Tascini, C., Iacoboni, C., Capone, A., Gattuso, G., Angarano, G., Petrelli, E., Grossi, P., Bartezaghi, M., & Zagni, E. (2012). Clinical experience with daptomycin in Italy: Results from a registry study of the treatment of Gram-positive infections between 2006 and 2009. Journal of Chemotherapy, 24(2), 113-121. https://doi.org/10.1179/1120009X12Z.00000000023